Sutro Biopharma (NASDAQ:STRO) Releases Earnings Results

Sutro Biopharma (NASDAQ:STRO) posted its earnings results on Tuesday. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.20, Yahoo Finance reports. The business had revenue of $25.71 million during the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative return on equity of 94.18% and a negative net margin of 74.61%.

Sutro Biopharma Trading Up 5.0 %

NASDAQ STRO traded up $0.16 on Wednesday, hitting $3.38. 339,151 shares of the company traded hands, compared to its average volume of 884,201. The company has a market capitalization of $276.45 million, a price-to-earnings ratio of -1.84 and a beta of 1.22. The business’s 50 day moving average price is $3.53 and its 200-day moving average price is $4.05. Sutro Biopharma has a 52-week low of $2.01 and a 52-week high of $6.13.

Analyst Ratings Changes

A number of analysts have commented on STRO shares. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a report on Wednesday. Bank of America assumed coverage on Sutro Biopharma in a research note on Wednesday, May 8th. They issued a “buy” rating and a $12.00 price target on the stock. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Sutro Biopharma in a research note on Tuesday, May 14th. Finally, Oppenheimer restated an “outperform” rating and issued a $10.00 price target on shares of Sutro Biopharma in a research note on Wednesday, May 15th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $12.50.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.